EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Advanced Breast Cancer Patients Treated with Trastuzumab Deruxtecan: A Real-World Study

Zhihao He iD, Yifei Chen, Guohong Song, Lijun Di, Xiaoning Wu iD, Jichun Song iD, Wei Zhang, Baichuan Cao iD, Qin Li iD, Bin Shao

Journal of Clinical Medicine · 29.10.2026 · 15 (21) · 8437

DOI: 10.3390/jcm15218437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.10.2026. Verfasst von Zhihao He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab deruxtecan (T-DXd) has redefined the treatment of HER2-positive advanced breast cancer (HER2+ ABC), yet responses remain heterogeneous and accessible biomarkers are lacking. The neutrophil-to-lymphocyte ratio (NLR) is an inexpensive, routinely available systemic inflammatory marker with established prognostic value in HER2-positive disease treated with anti-HER2 monoclonal antibodies; its prognostic significance in patients receiving the antibody–drug conjugate T-DXd remains undetermined.

Methods

This two-centre real-world study screened 146 consecutive patients with HER2+ ABC who received at least one cycle of T-DXd between January 2023 and June 2025 (data cutoff 16 October 2025) and enrolled 92 who met all eligibility criteria. The prespecified eligibility rule requiring a baseline complete blood count within 7 days before the first T-DXd dose was applied uniformly to every screened candidate; 34 candidates failed this rule (count drawn after the first dose, n = 16; drawn more than 7 days before, n = 17; collection date not recorded, n = 1) and one candidate was excluded because a baseline lymphocyte count at the assay lower limit rendered the derived ratio unreliable. The primary analysis evaluated baseline NLR as a continuous variable in Cox proportional-hazards regression for progression-free survival (PFS). Prespecified secondary analyses comprised median-split Kaplan–Meier analysis, quartile analysis with trend testing, individual blood components, and multivariable models. Prespecified sensitivity analyses, proportional-hazards testing, restricted cubic spline assessment of linearity, nested-model likelihood-ratio testing of the incremental value of NLR over the absolute lymphocyte count, and a centre-stratified analysis were performed. Exploratory subgroup analyses included interaction testing with false-discovery-rate correction.

Results

Of 146 screened patients, 92 were enrolled (54 excluded); 39 PFS events occurred. Median follow-up by reverse Kaplan–Meier was 7.6 months; overall median PFS was 9.82 months, with 6- and 12-month PFS rates of 73.7% (95% CI 62.3–82.1) and 37.1% (22.6–51.6). Each one-unit increase in baseline NLR was associated with a 37% higher hazard of progression or death (HR 1.37, 95% CI 1.12–1.69, p = 0.0028; C-index 0.672). At the cohort median cut-off (2.157), high NLR conferred shorter PFS than low NLR (median 7.66 vs. 11.50 months; HR 2.30, 95% CI 1.21–4.38; log-rank p = 0.0096). Quartile analysis showed a significant dose–response trend (HR per quartile 1.58, 95% CI 1.16–2.13, p for trend = 0.0033), with Q4 versus Q1 HR 4.14 (1.52–11.26, p = 0.0053). Among individual components, only the lymphocyte count showed a significant median-split association (log-rank p = 0.011), and NLR provided prognostic information beyond the lymphocyte count (likelihood-ratio p = 0.039) and beyond a clinically driven multivariable model (likelihood-ratio p = 0.014; ΔC-index +0.077). In the clinically driven multivariable model (n = 92, 7.8 events per variable), NLR remained an independent prognostic factor (HR 1.36, 95% CI 1.09–1.70, p = 0.0062), and estimates were consistent across a minimal model, two extended models and a ridge-penalised model. The association was consistent across both centres (interaction p = 0.73). Model assumptions were satisfied (Schoenfeld p = 0.75; non-linearity p = 0.46). No subgroup interaction remained significant after false-discovery-rate correction across 17 tests.

Conclusions

Elevated baseline NLR is an independent adverse prognostic marker for PFS among HER2+ ABC patients treated with T-DXd, and carries prognostic information beyond its individual blood components and beyond standard clinical variables. Because no comparator arm exists, NLR should be interpreted as a prognostic—not predictive—biomarker in this setting; prospective validation is required before any clinical application.

Schlagwörter

Stichwörter der Autor:innen

HER2-positive advanced breast cancerantibody–drug conjugatelymphocyte countneutrophil-to-lymphocyte ratioprognostic biomarkerreal-world studytrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
  • Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 Fuchen Road, Haidian District, Beijing 10…

ORCID-Profile: Zhihao He, Xiaoning Wu, Jichun Song, Baichuan Cao, Qin Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, Z., Chen, Y., Song, G., Di, L., Wu, X., Song, J., Zhang, W., Cao, B., Li, Q., & Shao, B. (2026). Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Advanced Breast Cancer Patients Treated with Trastuzumab Deruxtecan: A Real-World Study. Journal of Clinical Medicine, 15(21), 8437. https://doi.org/10.3390/jcm15218437

Vancouver

He Z, Chen Y, Song G, Di L, Wu X, Song J, et al. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Advanced Breast Cancer Patients Treated with Trastuzumab Deruxtecan: A Real-World Study. Journal of Clinical Medicine. 2026;15(21):8437. doi:10.3390/jcm15218437

BibTeX
@article{He2026,
  author = {He, Zhihao and Chen, Yifei and Song, Guohong and Di, Lijun and Wu, Xiaoning and Song, Jichun and Zhang, Wei and Cao, Baichuan and Li, Qin and Shao, Bin},
  title = {Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Advanced Breast Cancer Patients Treated with Trastuzumab Deruxtecan: A Real-World Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8437},
  doi = {10.3390/jcm15218437}
}
Kostenlos starten →